Logomix Inc. Logomix is transforming iPSC engineering with Geno-Writing™, a large-scale cellular system engineering platform. Purpose-built for ex vivo applications, Geno-Writing™ enables rapid, precise, and megabase-scale modifications in human iPSCs to maximize their therapeutic potential. The company is building technology to bring innovative, scalable cell treatments to patients worldwide.